eGenesis views success not as lifelong replacement but as buying patients time. One recipient of a pig kidney lived with it for nine months, recovered health, and then successfully received a human kidney, proving the value of xenotransplantation as a bridge therapy.
CEO Mike Curtis was hired for his 30-year track record of navigating the "bench-to-clinic" pathway with the FDA, not for domain expertise in transplantation. This highlights the value of process-oriented leadership when pioneering a completely new therapeutic modality.
A major unknown was the surgical procedure itself. After four cases, surgeons report that transplanting a pig kidney is remarkably similar to a human-to-human allogeneic transplant. This de-risks the surgical component significantly, with patients often leaving the ICU in one night.
The field was stalled by the risk of transmitting porcine retroviruses to humans. The problem was intractable because 50-70 viral copies are spread across the pig genome. CRISPR's unique ability to efficiently make that many edits was the specific breakthrough needed to mitigate this key safety risk.
Instead of using large commercial pigs and then editing genes to limit organ growth, eGenesis selected the Yucatan mini-pig breed from the start. This breed's organs naturally grow to a size compatible with human recipients, simplifying the genetic engineering required.
eGenesis prioritizes organs like kidneys and hearts because they show good outcomes in non-human primates and have high physiological similarity to humans. Livers are more challenging due to differences in synthetic function, dictating a different clinical approach (perfusion) instead of direct transplant.
Unlike direct-to-patient cell therapies, xenotransplantation's process of creating a pig serves as a biological filter. If gene edits have significant off-target effects, a healthy animal cannot be produced. This 'viable animal' checkpoint validates the genetic engineering before clinical use.
Instead of following a traditional, slower Phase 1/2/3 trial structure, eGenesis leveraged the FDA's Expanded Access (compassionate use) pathway for its initial human cases. This strategy allowed for rapid learning from real-world patients, putting them two years ahead of schedule.